£977k
+27%vs Dec 2023Active05304904Private limited companyBirmingham
CELENTYX LIMITED
Significant control: Professor Nicholas Mark Barnes (25–50%)
From public filings as at 31 Aug 2026; may contain errors or be out of date. Verify at Companies House · Terms
Coming soon · product and service lists
What does Celentyx Limited sell?
Registered activity: Research and experimental development on biotechnology (SIC 72110). We’re building product and service lists for UK companies. Get this one when it’s ready.
One email, only about this. If we don’t launch within 60 days we’ll tell you. Privacy
01
Summary
CELENTYX LIMITED is an active private limited company (company number 05304904) incorporated on 6 December 2004, registered in Birmingham. Its registered activity is research and experimental development on biotechnology (SIC 72110). Latest small accounts cover the period ending 31 December 2024, showing net assets of £977k and cash of £575k, with 13 employees on average. Net assets rose 27% on the prior period (£768k).
Peer position · net assets
By net assets it sits in the top quarter of 2,418 comparable companies in the UK (median £1,000, upper quartile £92k).
02
Ownership and control
- Professor Nicholas Mark Barnes
- owns 25–50% of shares
- Professor John Gordon
- owns 25–50% of shares
Persons with significant control hold 25% or more of shares or voting rights. Smaller shareholdings are only listed in confirmation-statement documents. Directors and secretaries: see the officers list at Companies House.
03
Key dates
- Incorporated
- 6 December 200421 yrs ago
- Next accounts due
- 30 September 202623 days overdue
- Confirmation statement due
- 20 December 2026in 58 days
Due dates are expected from Companies House filing rules; confirm on the official register before relying on them.
04
Activity
- SIC 72110
- Research and experimental development on biotechnology
- Accounts type
- Total Exemption Full
- Size band
- SmallCompanies Act thresholds
05
Financials
£575k
−23%vs Dec 2023Not reported
13
+8%vs Dec 2023| Period end | Net assets | Cash | Debtors | Creditors <1y | Turnover | Profit | Employees |
|---|---|---|---|---|---|---|---|
| 31 December 2024 | £977k | £575k | £609k | £263k | — | £206k | 13 |
| 31 December 2023 | £768k | £744k | £411k | £428k | — | £200k | 12 |
| 31 December 2022 | — | — | — | — | — | — | — |
Current ratio4.51Current assets ÷ creditors within one year
Cash per employee£44kCash ÷ average employees
Figures as filed in iXBRL accounts at Companies House. "—" means the line was not reported in that filing.
06
Filing and accounts signals
- Net assets above zeroNet assets £976,741 at 31 December 2024
- Net assets up 10% or more on the prior period+27.2% vs prior period
- Current assets at least 1.5× creditors within one yearCurrent ratio 4.51
- Cash at bank of £50,000 or moreCash £574,746
- Three or more accounting periods on record3 periods on record
- Incorporated five or more years agoIncorporated 6 December 2004
- Accounts past their due dateDue 30 September 2026
Neutral facts read from the register and filed accounts, each with its evidence. They are not a rating, a prediction or advice, and may be incomplete or out of date. How each signal is derived.
07
Timeline
- Confirmation statement duein 58 days
- Next accounts due23 days overdue
- Accounts period endNet assets £977k · small accounts
- Accounts period endNet assets £768k · small accounts
- Accounts period end
- Incorporated
08
Similar companies in Birmingham
- IMMUNEPEPTIDES LIMITEDBirmingham · inc. Aug 2008
- EUROFINS SELCIA LIMITEDWolverhampton · inc. Mar 2001
- STRIDEZ LIMITEDSutton Coldfield · inc. Jan 2009
- MARLBROOK (UK) LIMITEDBromsgrove · inc. Oct 2000
- CHROMA THERAPEUTICS LIMITEDBirmingham · inc. Sept 2000
- MICA BIOSYSTEMS LIMITEDSolihull · inc. Apr 2010
All companies incorporated on 6 December 2004 · in Dec 2004.
09
Reminders for CELENTYX LIMITED
Get an email before each filing deadline — accounts and confirmation statement — so nothing is late.